secwatch.observer — SEC 8-K summary
======================================

Issuer:     Metagenomi Therapeutics, Inc. (MGX)
CIK:        0001785279
Form:       8-K
Filed at:   2024-05-01T23:59:59+00:00
Accession:  0000950170-24-051238
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 1.02, 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Metagenomi ends Moderna collaboration; regains full rights to base editing/RIGS; reports $327.4M cash
--------------------------------------------------------------------------------

- Mutually terminated 2021 Strategic Collaboration and License Agreement with Moderna as of April 26, 2024.
- Metagenomi regains all development/commercialization rights to its wholly-owned base editing and RIGS programs.
- No further payments due from Moderna under the termination agreement; future revenue stream eliminated.
- Preliminary unaudited cash and cash equivalents of ~$327.4M as of March 31, 2024.
- Company will hold an investor call on May 1, 2024, with updated slide presentation (Exhibit 99.1).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785279/000095017024051238/0000950170-24-051238-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785279/000095017024051238/mgx-20240426.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-051238

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer